AU4657697A - Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (mpif-1), monocyte colony inhibitory factor (m-cif), and macrophage inhibitory factor-4 (mip-4) - Google Patents

Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (mpif-1), monocyte colony inhibitory factor (m-cif), and macrophage inhibitory factor-4 (mip-4)

Info

Publication number
AU4657697A
AU4657697A AU46576/97A AU4657697A AU4657697A AU 4657697 A AU4657697 A AU 4657697A AU 46576/97 A AU46576/97 A AU 46576/97A AU 4657697 A AU4657697 A AU 4657697A AU 4657697 A AU4657697 A AU 4657697A
Authority
AU
Australia
Prior art keywords
inhibitory factor
mpif
cif
mip
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU46576/97A
Other languages
English (en)
Inventor
Michael Antonaccio
Reiner L Gentz
Pablo Jimenez
Brent L. Kreider
Donna Mendrick
Vikram Patel
Jun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of AU4657697A publication Critical patent/AU4657697A/en
Priority to AU15446/02A priority Critical patent/AU775308B2/en
Priority to AU15445/02A priority patent/AU777297B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU46576/97A 1996-09-30 1997-09-30 Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (mpif-1), monocyte colony inhibitory factor (m-cif), and macrophage inhibitory factor-4 (mip-4) Abandoned AU4657697A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU15446/02A AU775308B2 (en) 1996-09-30 2002-02-06 Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1), monocyte colony inhibitory factor (M-CIF), and macrophage inhibitory factor-4 (MIP-4)
AU15445/02A AU777297B2 (en) 1996-09-30 2002-02-06 Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1), monocyte colony inhibitory factor (M-CIF), and macrophage inhibitory factor-4 (MIP-4)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2729996P 1996-09-30 1996-09-30
US2730096P 1996-09-30 1996-09-30
US60027299 1996-09-30
US50027300 1996-09-30
PCT/US1997/017505 WO1998014582A1 (en) 1996-09-30 1997-09-30 Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (mpif-1), monocyte colony inhibitory factor (m-cif), and macrophage inhibitory factor-4 (mip-4)

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU15445/02A Division AU777297B2 (en) 1996-09-30 2002-02-06 Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1), monocyte colony inhibitory factor (M-CIF), and macrophage inhibitory factor-4 (MIP-4)
AU15446/02A Division AU775308B2 (en) 1996-09-30 2002-02-06 Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1), monocyte colony inhibitory factor (M-CIF), and macrophage inhibitory factor-4 (MIP-4)

Publications (1)

Publication Number Publication Date
AU4657697A true AU4657697A (en) 1998-04-24

Family

ID=26702293

Family Applications (1)

Application Number Title Priority Date Filing Date
AU46576/97A Abandoned AU4657697A (en) 1996-09-30 1997-09-30 Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (mpif-1), monocyte colony inhibitory factor (m-cif), and macrophage inhibitory factor-4 (mip-4)

Country Status (8)

Country Link
EP (1) EP0941330A1 (zh)
JP (1) JP2001500382A (zh)
KR (1) KR20030097607A (zh)
CN (1) CN1239510A (zh)
AU (1) AU4657697A (zh)
CA (1) CA2267193A1 (zh)
NZ (2) NZ335003A (zh)
WO (1) WO1998014582A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU775308B2 (en) * 1996-09-30 2004-07-29 Human Genome Sciences, Inc. Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1), monocyte colony inhibitory factor (M-CIF), and macrophage inhibitory factor-4 (MIP-4)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6488925B2 (en) 1993-12-22 2002-12-03 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polypeptides
US6451562B1 (en) 1993-12-22 2002-09-17 Human Genome Sciences, Inc. Polypeptides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) polynucleotides
US6001606A (en) * 1994-03-08 1999-12-14 Human Genome Sciences, Inc. Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6495129B1 (en) 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
US6632425B1 (en) 1997-03-20 2003-10-14 Human Genome Sciences, Inc. Chemokine compositions
US6495128B1 (en) 1998-11-10 2002-12-17 Human Genome Sciences, Inc. Human chemokine β-7 deletion and substitution proteins
EP1142908A4 (en) * 1999-01-07 2002-05-22 Takeda Chemical Industries Ltd PROCESS FOR PRODUCING ACTIVATED PROTEINS
AU1083401A (en) * 1999-10-14 2001-04-23 Human Genome Sciences, Inc. Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1)
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
KR100867257B1 (ko) * 2001-10-09 2008-11-11 케모센트릭스, 인크. 포밀 펩티드 수용체 유사 1 수용체에 대한 리간드로유용한 조성물 및 이의 사용 방법
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
EP1675870A1 (en) * 2003-10-24 2006-07-05 IPF Pharmaceuticals GmbH Human chemokine hcc-1 polypeptides to improve stem cell transplantation
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
EP1738175A2 (en) * 2004-03-22 2007-01-03 Novartis AG Chemokine ccl18 as a biomarker
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
EP2208072B1 (en) * 2007-10-22 2015-07-01 St Vincent's Hospital Sydney Limited Methods of prognosis
CN113215085B (zh) * 2021-05-07 2024-05-10 澳门大学 一种脂类物质添加剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2214484T3 (es) * 1993-12-22 2004-09-16 Human Genome Sciences, Inc. Proteinas inflamatorias de macrofagos mip-3, mip-4 y mip-1 gamma.
US20030105293A1 (en) * 1993-12-24 2003-06-05 Wolf-Georg Forssmann Human circulating cytokine cc-1
US5602008A (en) * 1994-11-29 1997-02-11 Incyte Pharmaceuticals, Inc. DNA encoding a liver expressed chemokine
MX9708537A (es) * 1995-05-05 1998-02-28 Human Genome Sciences Inc Quimiocina beta-8 quimiocina beta-1 y proteina-4 inflamatoria de los macrofagos, humanas.
JPH11512610A (ja) * 1995-09-29 1999-11-02 スミスクライン・ビーチャム・コーポレイション 短縮形ケモカインβ−８
WO1997015594A1 (en) * 1995-10-24 1997-05-01 Smithkline Beecham Corporation Novel chemokine for mobilizing stem cells

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU775308B2 (en) * 1996-09-30 2004-07-29 Human Genome Sciences, Inc. Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1), monocyte colony inhibitory factor (M-CIF), and macrophage inhibitory factor-4 (MIP-4)
AU777297B2 (en) * 1996-09-30 2004-10-07 Human Genome Sciences, Inc. Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1), monocyte colony inhibitory factor (M-CIF), and macrophage inhibitory factor-4 (MIP-4)

Also Published As

Publication number Publication date
CN1239510A (zh) 1999-12-22
NZ335003A (en) 2000-11-24
WO1998014582A1 (en) 1998-04-09
JP2001500382A (ja) 2001-01-16
CA2267193A1 (en) 1998-04-09
KR20030097607A (ko) 2003-12-31
EP0941330A1 (en) 1999-09-15
NZ506135A (en) 2002-11-26

Similar Documents

Publication Publication Date Title
AU4657697A (en) Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (mpif-1), monocyte colony inhibitory factor (m-cif), and macrophage inhibitory factor-4 (mip-4)
AU5171696A (en) Device, compounds, algorithms, and methods of molecular characterization and manipulation with molecular parallelism
EP0710667B8 (de) Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
AU5175999A (en) Anesthetic injection apparatus
AU2459697A (en) Anaerobic treatment process
HK1026100A1 (en) Video decoder with interleaved data processing.
AU4792593A (en) Single-chamber cleaning, rinsing and drying apparatus
ZA973022B (en) New pharmaceutical composition with anaesthetic effect.
AU4555097A (en) Compounds with antimycotic and cytostatic effect, preparation method, agent containing these compounds and dsm 11 092
AU4734497A (en) Graft survival prolongation with porphyrins
DK0884964T3 (da) Stol, navnlig en kontorstol
ITMI950538V0 (it) Seggiolone con meccanismo perfezionato di reclinamento
AU2728997A (en) Use of alkylaryl polyether alcohol polymers for the treatment of chronic pulmonary inflammation
AU1041097A (en) Encoder, decoder and methods used therefor
AU1743495A (en) Composition for wound healing, neuron growth and vascularization
AU5123996A (en) Bactericidal mat, process for producing the same, and use thereof
NO20031525L (no) Kjemokinmutanter i behandlingen av multippel sklerose
AU5106696A (en) Novel, defined enzyme mixtures for obtaining cells and for wound treatment
AU7552098A (en) Physiologically active substances tkr2449, process for producing the same, and microorganism
DE69217783D1 (de) 3-Phenoxybenzyl(iden)pyrrolidin-Derivate, deren Herstellung und deren Verwendung als muskarin-cholinerge Mittel
AU4302496A (en) Spindle, in particular extrusion spindle, composed of segments
AU2290801A (en) Hardware token self enrollment process
AU2001236858A1 (en) Distribution, processing, and reconstruction of variable-sized images using multiple processor arrays
AU2553397A (en) Method and composition for cleansing wounds with minimal cytotoxicity for minimal scarring
AU2303495A (en) Preservative for wood, treating solutions and use of the preservative

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted